Skip to main content

Ticlopidine Pregnancy and Breastfeeding Warnings

Brand names: Ticlid

Ticlopidine Pregnancy Warnings

Ticlopidine has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity, however, dosages of 200 to 400 mg/kg/day resulted in maternal and fetal toxicity. There are no controlled data in human pregnancy. Ticlopidine should be given during pregnancy only when benefit outweighs the risk.

See references

Ticlopidine Breastfeeding Warnings

There are no data on the excretion of ticlopidine into human milk. Animal studies have shown ticlopidine to be excreted in rat milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc. 2001;PROD.

References for breastfeeding information

  1. Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer